BioLineRx logo
BioLineRx
BLRX | NASDAQ
Chart Builder DCF Calculator
$1.19
-$0.11 (-8.46%)
At close: Nov 16, 2026, 3:59 PM ET
$1.16
-$0.03 (-2.39%)
After-hours: Nov 16, 2026, 7:30 PM ET

BioLineRx Company Profile

Company profile explained

Company Profile

BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.

Key Executives

Name Position
Philip A. Serlin Chief Executive Officer
Mali Zeevi Chief Financial Officer
Ella Sorani Chief Development Officer
John Lacey Head of Corporation Communications & Investor Relations
Raziel Fried Treasurer & Budgetary Control Director

Latest SEC Filings

Date Type Title
Oct 23, 2026 6-K Filing
Oct 02, 2026 EFFECT Filing
Oct 02, 2026 424B3 Filing
Sep 25, 2026 F-1 Filing
Sep 24, 2026 6-K Filing
Sep 10, 2026 6-K Filing
Sep 09, 2026 D Filing
Aug 31, 2026 424B5 Filing
Aug 31, 2026 6-K Filing
Aug 31, 2026 6-K Filing
View All SEC Filings ➞
BioLineRx
BioLineRx logo
Country Israel
IPO Date Jul 27, 2011
Industry Biotechnology
Sector Healthcare
Employees 22
CEO Philip A. Serlin

Contact Details

Modi’in Technology Park Hevel Modi'in, HM 7177871 Israel

Stock Details

Ticker Symbol BLRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001498403
CUSIP Number 09071M304
ISIN Number US09071M3043
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.